Loading...
XOSL
PHO
Market cap139mUSD
Apr 30, Last price  
53.60NOK
1D
-0.92%
1Q
-3.94%
Jan 2017
27.62%
Name

Photocure ASA

Chart & Performance

D1W1MN
P/E
—
P/S
2.77
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.76%
Rev. gr., 5y
13.29%
Revenues
525m
+4.94%
53,641,000210,320,00099,006,000102,220,00048,428,000177,357,000115,568,000133,823,00083,616,000128,952,000134,717,000143,627,000150,911,000181,510,000281,556,000256,482,000360,540,000393,132,000500,657,000525,388,000
Net income
-5m
L
-38,210,00085,082,000-74,970,000-64,382,000312,382,00018,092,000-7,512,000-47,901,000-58,950,000-24,700,000-36,178,00035,309,000-34,697,000-36,708,00031,832,000-22,403,000-30,897,000-71,857,000979,000-4,810,000
CFO
77m
+58.88%
-70,540,00066,326,000-95,655,000-59,677,000317,444,00015,597,000-34,466,000-54,928,000-99,722,000-6,088,000-21,032,00019,193,000-23,593,000-24,124,00020,655,00015,585,00023,886,000-2,018,00048,309,00076,751,000
Dividend
May 23, 20132 NOK/sh
Earnings
May 13, 2025

Profile

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
URL
https://photocure.com/
IPO date
May 29, 2000
Employees
87
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
525,388
4.94%
500,657
27.35%
393,132
9.04%
Cost of revenue
389,385
375,762
329,473
Unusual Expense (Income)
NOPBT
136,003
124,895
63,659
NOPBT Margin
25.89%
24.95%
16.19%
Operating Taxes
13,199
8,761
723
Tax Rate
9.70%
7.01%
1.14%
NOPAT
122,804
116,134
62,936
Net income
(4,810)
-591.32%
979
-101.36%
(71,857)
132.57%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,580
BB yield
-0.26%
Debt
Debt current
5,613
18,282
Long-term debt
33,561
48,294
Deferred revenue
Other long-term liabilities
139,656
132,003
130,989
Net debt
(293,852)
(217,162)
(198,075)
Cash flow
Cash from operating activities
76,751
48,309
(2,018)
CAPEX
(2,459)
(12,306)
(3,609)
Cash from investing activities
1,422
(594)
(1,462)
Cash from financing activities
(43,822)
(56,284)
(51,342)
FCF
133,506
90,823
68,147
Balance
Cash
293,852
256,336
264,651
Long term investments
Excess cash
267,583
231,303
244,994
Stockholders' equity
22,705
22,276
22,436
Invested Capital
617,198
612,162
606,237
ROIC
19.98%
19.06%
10.33%
ROCE
21.25%
19.69%
10.13%
EV
Common stock shares outstanding
27,552
27,133
27,035
Price
62.00
-8.01%
67.40
-36.89%
106.80
3.99%
Market cap
1,708,248
-6.59%
1,828,798
-36.66%
2,887,336
4.73%
EV
1,414,396
1,611,636
2,689,261
EBITDA
164,801
152,582
88,037
EV/EBITDA
8.58
10.56
30.55
Interest
36,901
26,327
25,804
Interest/NOPBT
27.13%
21.08%
40.53%